ANKRD1 | Ankyrin repeat domain 1 (cardiac muscle) | Disease related genes
| | | | | Tissue enriched |
MYO18B | Myosin XVIIIB | | | | | | Group enriched |
MYH7 | Myosin, heavy chain 7, cardiac muscle, beta | Candidate cardiovascular disease genes Disease related genes Plasma proteins
| | | | | Group enriched |
UNC45B | Unc-45 homolog B (C. elegans) | | | | | | Group enriched |
SYNPO2L | Synaptopodin 2-like | Cytoskeleton related proteins Plasma proteins
| | | | | Group enriched |
MYOM2 | Myomesin 2 | | | | | | Group enriched |
ANKRD2 | Ankyrin repeat domain 2 (stretch responsive muscle) | | | | | | Group enriched |
TNNC1 | Troponin C type 1 (slow) | Disease related genes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
PDE4DIP | Phosphodiesterase 4D interacting protein | Cancer-related genes Disease related genes
| | | | | Group enriched |
MLF1 | Myeloid leukemia factor 1 | Cancer-related genes Disease related genes
| | | | | Group enriched |
MYH6 | Myosin, heavy chain 6, cardiac muscle, alpha | Candidate cardiovascular disease genes Disease related genes Plasma proteins
| | | | | Tissue enriched |
TYRP1 | Tyrosinase-related protein 1 | Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets RAS pathway related proteins
| | | | | Group enriched |
POPDC3 | Popeye domain containing 3 | Predicted membrane proteins
| | | | | Group enriched |
SPTB | Spectrin, beta, erythrocytic | Disease related genes Plasma proteins
| | | | | Group enriched |
SGCG | Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) | Cytoskeleton related proteins Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
CORO6 | Coronin 6 | | | | | | Group enriched |
FHL2 | Four and a half LIM domains 2 | | | | | | Group enriched |
SH3RF2 | SH3 domain containing ring finger 2 | | | | | | Group enriched |
ZNF106 | Zinc finger protein 106 | Plasma proteins
| | | | | Group enriched |
ALPK2 | Alpha-kinase 2 | Cancer-related genes Enzymes
| | | | | Tissue enhanced |
CDH2 | Cadherin 2, type 1, N-cadherin (neuronal) | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CLGN | Calmegin | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CRYAB | Crystallin, alpha B | Cancer-related genes Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
DKK3 | Dickkopf WNT signaling pathway inhibitor 3 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FAM110B | Family with sequence similarity 110, member B | | | | | | Tissue enhanced |
HSPB8 | Heat shock 22kDa protein 8 | Disease related genes
| | | | | Tissue enhanced |
NES | Nestin | Plasma proteins
| | | | | Tissue enhanced |
OXCT1 | 3-oxoacid CoA transferase 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PKP2 | Plakophilin 2 | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
PPFIA4 | Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4 | Plasma proteins
| | | | | Tissue enhanced |
SORBS2 | Sorbin and SH3 domain containing 2 | | | | | | Tissue enhanced |